On 6 3, Beijing Shougang Langze Technology Co., Ltd. officially listed on the Main Board of The Stock Exchange of Hong Kong Limited.

This is not just a routine IPO. Shougang Langze's listing has set at least three new records:The first company in the global CCUS (Carbon Capture, Utilization, and Storage) sector to commercialize synthetic biotechnology, the 7th Hong Kong-listed subsidiary of Shougang Group, and the "Global ESG First Stock" on the Hong Kong stock market.From its inception in 2011 to its listing in 2026, Shougang Group has once again achieved a major milestone in advancing the industrialization of green and low-carbon technologies and empowering real-economy industry upgrades through capital operations.

But behind this dazzling IPO story lies a fundamental shift in the underlying logic of China's bio-manufacturing. In just 15 years, Shougang Langze has proven one thing:Synthetic biotechnology, once deemed "impossible to industrialize," is now transforming carbon-intensive industries into carbon resource factories. 。

From Lab to Factory

A technological breakthrough that was widely predicted to fail.

In 2011, Shougang Lanza was founded amid the green technology wave, introducing a bio-fermentation process that converts industrial off-gas into ethanol. At the time, many in the industry doubted its commercial viability because, although the technology had been successfully developed in the lab, it had not yet undergone pilot testing.

从实验室到大规模生产，从来不是一条平坦的直线。首钢朗泽开辟的是一条全球独有的工业尾气资源化商业路径：不以传统环保企业或单一生物制造公司的业务逻辑定义自己，而是用“A unified technical architecture integrating CCUS carbon capture as the foundation, synthetic biology as the core process, and AI-driven intelligent control as the engine.，Turn industrial exhaust from the steel and ferrous alloy sectors into valuable resources.

Under the industrial resources and scenario support of Shougang Group, the company has built aGen 1 carbon reduction + Gen 2 negative carbon”双技术架构。通过AI Big Data Analytics and Simulation ModelsIntelligently optimize strain cultivation, off-gas component monitoring, and the entire fermentation process to continuously improve carbon conversion efficiency. Leveraging proprietary synthetic biology strain technology, industrial waste gas that was previously vented directly is converted via biological fermentation intoHigh-Purity Bioethanol and Novel Microbial Protein两大核心产品——彻底跳出乙醇生产依赖玉米、甘蔗等粮食原料的传统模式。

In addition, bioethanol can be further processed intoSAF Sustainable Aviation Fuel, directly supplying the global aviation industry's critical need for decarbonization; microbial protein has secured China's first new feed product certificate, with crude protein content ≥ 80%, effectively replacing imported soybean meal at the source.Ensure national food security。此次IPO募集资金重点投向河北二期负碳项目与SAF新产线建设，产品去向和资本投向高度一致。

三点构成了一个完美的“碳闭环”商业模型：废气的来源是自家产业链（首钢集团），产品的增值路径早已铺好（乙醇→SAF、微生物蛋白→饲料），募资投向又在扩充应用场景。

Once fully commercialized, this technology will drive three transformative shifts: carbon emission reductions in the industrial sector, clean fuel alternatives for aviation, and self-sufficient feed protein production.

[ 从钢铁巨头到绿色科技资本局] .

把时间尺度拉长，首钢朗泽的故事不只是一家企业的上市。

它背后有两个更宏大的趋势正在交汇。一个是中国“双碳”战略deepening implementation; policy-level encouragement for the integrated development of CCUS technology with synthetic biology and resource recycling technologies; another is合成生物学As the most disruptive biomanufacturing technology of the 21th century, it is transitioning from laboratory research to large-scale industrialization, reshaping the paradigm of industrial production.

The industrial revolution under the "Dual Carbon" goals is, at its core, a revolution in revaluing carbon resources. Shougang Langze's listing marks that this revolution has moved from concept to capital validation. From a startup in 2011 to a global benchmark for CCUS + biomanufacturing in 2026, Shougang Langze has proven one thing in just 15 years:When synthetic biology meets industrial applications, turning carbon into gold is no longer science fiction—it's happening now.。

2026 (2nd) EMBC Bio-Manufacturing Industry Conference & Exhibition (Summer)

2026 (2nd) EMBC Bio-Manufacturing Industry Conference & Exhibition (Summer)将于8 27-28Held in Shanghai, the exhibition will invite2000+ Attendees,100+Speaker,20+Premium exhibitors, featuring "展览-产品-大会-合作Four core modules focused on "breakthroughs in fundamental research + cross-domain industrial implementation."

Whether you are an entrepreneur, investor, technical expert, or procurement decision-maker in the bio-manufacturing sector, this exhibition offers a platform to explore the latest policy trends and industry developments, connect with top-tier capital and high-quality projects, and showcase cutting-edge technologies and innovative products.